T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Chimeric antigen receptor (CAR) T-cell therapies have proved effective in several haematological cancers including B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, multiple myeloma ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...

ASH 2024 meeting. Well-tolerated treatment with no severe adverse events. Early CD8+ T cell expansion may predict positive clinical outcomes. Findings support EO2463 as a proactive treatment option ...

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

The study evaluated Yescarta in patients with relapsed/refractory non-NHL, including follicular lymphoma or marginal zone lymphoma. The data was presented at the 66th American Society of Hematology ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone ...

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per ...